Advertisement
Pearls

Antimicrobial Peptides: Primeval Molecules or Future Drugs?

  • Brian M. Peters,

    Affiliations: Graduate Program in Life Sciences, Microbiology and Immunology Program, School of Medicine, University of Maryland, Baltimore, Maryland, United States of America, Department of Microbial Pathogenesis, Dental School, University of Maryland, Baltimore, Maryland, United States of America

    X
  • Mark E. Shirtliff,

    Affiliations: Department of Microbial Pathogenesis, Dental School, University of Maryland, Baltimore, Maryland, United States of America, Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, United States of America

    X
  • Mary Ann Jabra-Rizk mail

    mrizk@umaryland.edu

    Affiliation: Department of Oncology and Diagnostic Sciences, University of Maryland–Baltimore, Maryland, United States of America

    X
  • Published: October 28, 2010
  • DOI: 10.1371/journal.ppat.1001067
  • Published in PLOS Pathogens

About the Authors

Brian M. Peters
Graduate Program in Life Sciences, Microbiology and Immunology Program, School of Medicine, University of Maryland, Baltimore, Maryland, United States of America
Brian M. Peters, Mark E. Shirtliff
Department of Microbial Pathogenesis, Dental School, University of Maryland, Baltimore, Maryland, United States of America
Mark E. Shirtliff
Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, United States of America
Mary Ann Jabra-Rizk
Department of Oncology and Diagnostic Sciences, University of Maryland–Baltimore, Maryland, United States of America

Corresponding Author

Email: mrizk@umaryland.edu

Competing Interests

The authors have declared that no competing interests exist.